瓦莫罗酮治疗杜氏肌营养不良男孩48周以上的疗效与安全性:一项随机对照试验
这项随机双盲安慰剂和泼尼松对照试验纳入121例4至7岁以下杜氏肌营养不良男孩,评估瓦莫罗酮2 mg/kg/d和6 mg/kg/d治疗48周的疗效与安全性。6 mg/kg/d瓦莫罗酮在48周时维持了所有运动结局的改善,且泼尼松导致的生长迟滞和骨转换标志物下降在换用瓦莫罗酮后逆转。
要点
- 6 mg/kg/d瓦莫罗酮治疗48周维持了24周时观察到的所有运动结局改善。
- 2 mg/kg/d与6 mg/kg/d瓦莫罗酮在NSAA上改善相似,但其他运动结局改善较少。
- 泼尼松换用瓦莫罗酮后,生长迟滞和骨转换标志物下降出现逆转。
核心结论
- 6 mg/kg/d瓦莫罗酮治疗24周所见的运动结局改善维持至48周。
- 6 mg/kg/d瓦莫罗酮在大多数(3/5)运动结局上较2 mg/kg/d显示出更好的效果维持。
- 泼尼松导致的骨病变(生长迟滞和血清骨生物标志物下降)在换用瓦莫罗酮后逆转。
研究设计与样本
- 随机、双盲、安慰剂对照和泼尼松对照临床试验,评估两种剂量瓦莫罗酮。
- 纳入基线年龄4岁至7岁以下的杜氏肌营养不良参与者,共121例随机分组。
- 干预为瓦莫罗酮2 mg/kg/d和6 mg/kg/d治疗48周(第1期24周+第2期24周),泼尼松0.75 mg/kg/d和安慰剂治疗前24周(交叉前)。
- 疗效通过粗大运动结局评估,安全性通过不良事件、生长速度、体重指数和骨转换生物标志物评估。
主要发现
- 6 mg/kg/d瓦莫罗酮组主要结局从仰卧位站起速度第24周最小二乘均值(SE)0.052(0.0130)次/秒 vs 第48周最小二乘均值(SE)0.0446(0.0138)次/秒。
- 48周后,2 mg/kg/d与6 mg/kg/d瓦莫罗酮在North Star步行评估(NSAA)上改善相似:瓦莫罗酮6 mg/kg/d-瓦莫罗酮2 mg/kg/d最小二乘均值(SE)0.49(1.14),95%CI -1.80至2.78,p=0.67。
- 安慰剂换用瓦莫罗酮6 mg/kg/d组在治疗20周后快速改善,在仰卧位站起、跑/走10米时间和NSAA上接近48周6 mg/kg/d瓦莫罗酮治疗的获益。
- 泼尼松换用瓦莫罗酮6 mg/kg/d组交叉后线性生长显著改善,两个交叉组中泼尼松诱导的骨转换生物标志物下降均快速逆转。
- 两个瓦莫罗酮组治疗24周后体重指数增加,随后稳定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Vamorolone is a dissociative agonist of the glucocorticoid receptor that has shown similar efficacy and reduced safety concerns in comparison with prednisone in Duchenne muscular dystrophy (DMD). This study was conducted to determine the efficacy and safety of vamorolone over 48 weeks and to study crossover participants (prednisone to vamorolone; placebo to vamorolone). METHODS: A randomized, double-blind, placebo-controlled and prednisone-controlled clinical trial of 2 doses of vamorolone was conducted in participants with DMD, in the ages from 4 years to younger than 7 years at baseline. The interventions were 2 mg/kg/d of vamorolone and 6 mg/kg/d of vamorolone for 48 weeks (period 1: 24 weeks + period 2: 24 weeks) and 0.75 mg/kg/d of prednisone and placebo for the first 24 weeks (before crossover). Efficacy was evaluated through gross motor outcomes and safety through adverse events, growth velocity, body mass index (BMI), and bone turnover biomarkers. This analysis focused on period 2. RESULTS: A total of 121 participants with DMD were randomized. Vamorolone at a dose of 6 mg/kg/d showed maintenance of improvement for all motor outcomes to week 48 (e.g., for primary outcome, time to stand from supine [TTSTAND] velocity, week 24 least squares mean [LSM] [SE] 0.052 [0.0130] rises/s vs week 48 LSM [SE] 0.0446 [0.0138]). After 48 weeks, vamorolone at a dose of 2 mg/kg/d showed similar improvements as 6 mg/kg/d for North Star Ambulatory Assessment (NSAA) (vamorolone 6 mg/kg/d-vamorolone 2 mg/kg/d LSM [SE] 0.49 [1.14]; 95% CI -1.80 to 2.78, p = 0.67), but less improvement for other motor outcomes. The placebo to vamorolone 6 mg/kg/d group showed rapid improvements after 20 weeks of treatment approaching benefit seen with 48-week 6 mg/kg/d of vamorolone treatment for TTSTAND, time to run/walk 10 m, and NSAA. There was significant improvement in linear growth after crossover in the prednisone to vamorolone 6 mg/kg/d group, and rapid reversal of prednisone-induced decline in bone turnover biomarkers in both crossover groups. There was an increase in BMI after 24 weeks of treatment that then stabilized for both vamorolone groups. DISCUSSION: Improvements of motor outcomes seen with 6 mg/kg/d of vamorolone at 24 weeks of treatment were maintained to 48 weeks of treatment. Vamorolone at a dose of 6 mg/kg/d showed better maintenance of effect compared with vamorolone at a dose of 2 mg/kg/d for most (3/5) motor outcomes. Bone morbidities of prednisone (stunting of growth and declines in serum bone biomarkers) were reversed when treatment transitioned to vamorolone. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT03439670. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for boys with DMD, the efficacy of vamorolone at a dose of 6 mg/kg/d was maintained over 48 weeks.
引用
- Dang UJ, Damsker JM, Guglieri M, et al. Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial. Neurology. 2024. PMID: 38335499. doi:10.1212/WNL.0000000000208112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。